Kura Oncology, Inc. (KURA) Financial Statements (2024 and earlier)

Company Profile

Business Address 12730 HIGH BLUFF DRIVE, SUITE 400
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments437,985,000517,960,000633,320,000236,891,000178,985,00093,145,000
Cash and cash equivalents51,802,00090,672,000325,493,00026,135,00016,119,00011,433,000
Short-term investments386,183,000427,288,000307,827,000210,756,000162,866,00081,712,000
Receivables    30,000224,000216,000
Other undisclosed current assets8,441,0004,329,0003,972,0002,682,0001,988,0001,280,000
Total current assets:446,426,000522,289,000637,292,000239,603,000181,197,00094,641,000
Noncurrent Assets
Operating lease, right-of-use asset3,842,0005,573,0006,334,000 
Property, plant and equipment2,540,0002,673,0002,021,00044,000(92,000)10,000
Restricted cash and investments 210,000210,000210,000   
Other noncurrent assets3,288,0003,306,0001,355,0002,325,0001,182,0001,200,000
Other undisclosed noncurrent assets     92,000 
Total noncurrent assets:9,880,00011,762,0009,920,0002,369,0001,182,0001,210,000
TOTAL ASSETS:456,306,000534,051,000647,212,000241,972,000182,379,00095,851,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:21,739,00022,455,00023,024,00015,314,00013,385,0008,284,000
Employee-related liabilities7,923,0007,016,0003,694,0003,437,0002,345,000
Accounts payable1,533,0003,236,0002,753,0003,526,0003,890,0001,248,000
Accrued liabilities12,736,0001,073,0001,505,0001,124,000508,000839,000
Other undisclosed accounts payable and accrued liabilities7,470,00010,223,00011,750,0006,970,0005,550,0003,852,000
Debt   3,000,000250,000 1,531,000
Other undisclosed current liabilities2,318,000   230,000216,000
Total current liabilities:24,057,00022,455,00026,024,00015,564,00013,615,00010,031,000
Noncurrent Liabilities
Long-term debt and lease obligation9,158,0004,612,0009,888,0007,250,0007,500,0005,567,000
Long-term debt, excluding current maturities9,158,000 4,250,0007,250,0007,500,0005,567,000
Liabilities, other than long-term debt2,813,000375,000395,000377,000279,000388,000
Other liabilities265,000375,000395,000377,000279,000388,000
Operating lease, liability2,548,0004,612,0005,638,000 
Total noncurrent liabilities:11,971,0004,987,00010,283,0007,627,0007,779,0005,955,000
Total liabilities:36,028,00027,442,00036,307,00023,191,00021,394,00015,986,000
Equity
Equity, attributable to parent420,278,000506,609,000610,905,000218,781,000160,985,00079,865,000
Common stock7,0007,0007,0005,0004,0003,000
Additional paid in capital997,111,000941,359,000913,354,000431,322,000310,849,000169,201,000
Accumulated other comprehensive income (loss)(8,032,000)(1,789,000)46,000331,000(131,000)(49,000)
Accumulated deficit(568,808,000)(432,968,000)(302,502,000)(212,877,000)(149,737,000)(89,290,000)
Total equity:420,278,000506,609,000610,905,000218,781,000160,985,00079,865,000
TOTAL LIABILITIES AND EQUITY:456,306,000534,051,000647,212,000241,972,000182,379,00095,851,000

Income Statement (P&L) (USD)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Operating expenses(139,865,000)(131,258,000)(91,899,000)(67,479,000)(62,883,000)(36,077,000)
Operating loss:(139,865,000)(131,258,000)(91,899,000)(67,479,000)(62,883,000)(36,077,000)
Nonoperating income4,025,000792,0002,274,0004,339,0002,436,000643,000
Investment income, nonoperating      751,000
Interest and debt expense(229,000)(212,000)(578,000)(580,000)(498,000)(888,000)
Loss from continuing operations:(136,069,000)(130,678,000)(90,203,000)(63,720,000)(60,945,000)(36,322,000)
Loss before gain (loss) on sale of properties:(130,678,000)(90,203,000)(63,720,000)(60,945,000)(36,322,000)
Net loss:(136,069,000)(130,678,000)(90,203,000)(63,720,000)(60,945,000)(36,322,000)
Other undisclosed net income attributable to parent229,000212,000578,000580,000498,000888,000
Net loss available to common stockholders, diluted:(135,840,000)(130,466,000)(89,625,000)(63,140,000)(60,447,000)(35,434,000)

Comprehensive Income (USD)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(136,069,000)(130,678,000)(90,203,000)(63,720,000)(60,945,000)(36,322,000)
Other comprehensive income (loss)(6,243,000)(1,835,000)(285,000)462,000(82,000) 
Comprehensive loss:(142,312,000)(132,513,000)(90,488,000)(63,258,000)(61,027,000)(36,322,000)
Other undisclosed comprehensive income, net of tax, attributable to parent229,000212,000578,000580,000498,000857,000
Comprehensive loss, net of tax, attributable to parent:(142,083,000)(132,301,000)(89,910,000)(62,678,000)(60,529,000)(35,465,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: